ArriVent Biopharma initiated with a Buy at Truist

Truist initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $43 price target ArriVent is advancing firmonertinib, an already China-approved and U.S. Breakthrough-designated inhibitor for hard-to-treat, mutation-driven lung cancers, with two global pivotal trials underway and topline FURVENT data expected in early 2026, the analyst tells investors in a research note. The company appears positioned for more than $1B peak sales potential and additional pipeline value not yet reflected in its share price, Truist argues.